Combination Chemotherapy for Recurrent Ovarian Cancer
Name of the Trial
Why Is This Trial Important?
Ovarian cancer that remains progression-free for more than 6 months after completion of chemotherapy is called platinum-sensitive. Patients who have a recurrence of platinum-sensitive disease will likely benefit from another round of platinum therapy, which may be given in combination with a non-platinum agent.
Primary peritoneal cancer grows in the peritoneum, a membrane that lines the walls of the abdomen. It is biologically similar to ovarian epithelial cancer.
This trial will study the effectiveness of carboplatin with or without pegylated liposomal doxorubicin in treating patients with recurrent ovarian epithelial or primary peritoneal cancer.
"Whether two-drug combinations are superior to single agent carboplatin in platinum-sensitive disease remains a critical, unanswered question in the management of women experiencing recurrent advanced disease," said Dr. Alberts.
Who Can Join This Trial?
Where Is This Trial Taking Place?
Who to Contact
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.